



**Metrion Biosciences appoints Dr Rory Curtis as
Vice President US Commercial Operations**

*Appointment supports the next phase of growth within United States
for ion channel contract research and drug discovery services*

Cambridge, UK, 30 November 2021: Metrion Biosciences Limited ("Metrion"), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Rory Curtis as Vice President US Commercial Operations. The appointment represents the next phase in the Company's expansion plans and business growth, driven by its ion channel discovery capabilities.

Rory is based in Buffalo, NY, and will be responsible for Metrion's business development operations throughout the United States, including supporting and expanding the Company's existing client base and leading the development of new business opportunities in the ion channel field.

Rory has a strong background in drug discovery and development, as well as in global business development. He spent 25 years in the management of drug discovery projects with increasing levels of responsibility at Regeneron, Millennium, Elixir and Cubist Pharmaceuticals. He was responsible for the ion channel discovery platform at Millennium and the TRPA1 program at Cubist, which yielded a Phase I clinical candidate. In 2015, he moved into contract research operations and sales with AMRI (now Curia) and the Hauptman-Woodward Institute. Rory received his undergraduate degree in Zoology and PhD in Biochemistry from Imperial College of Science, Technology and Medicine in London, UK.

Nick Foster, Chief Commercial Officer, Metrion Biosciences, said: "I am very pleased to welcome Rory to Metrion. Engaging with and supporting our clients in their research is Metrion's top priority; Rory's background and extensive experience enhances our ability to provide local support in the United States."

Dr Rory Curtis, Vice President US Commercial Operations, Metrion Biosciences, commented: "Metrion's expansion in the North American market is an exciting phase in the development of the business. I am looking forward to joining the team at this pivotal stage and supporting Metrion's goal to become the leading global ion channel services provider."

For more information: <https://www.metrionbiosciences.com/>

-ENDS-

Notes to Editors



*Nick Foster, Chief Commercial Officer,
Metrion Biosciences*



*Dr Rory Curtis, Vice President US
Commercial Operations, Metrion
Biosciences*

For high resolution images please contact Zyme Communications

Media contact:

Lily Jeffery

Zyme Communications

E-mail: lily.jeffery@zymecommunications.com

Tel: +44 (0)7891 477 378

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please [click here](#).

About Metrion Biosciences

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences' ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages.

For more information, please visit www.metrionbiosciences.com

LinkedIn: [@metrion-biosciences](#) | Twitter: [@metrion_biosci](#)